Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Modipafant · UK-74505

Small molecule

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is Modipafant?

Modipafant (UK-74505) is a drug studied in dengue fever, dosed as 50 mg or 100 mg every 12 hours alternating with placebo over 5 days.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
UK-74505
Drug type
Small molecule
Therapy area
Infectious disease
In trials of
SXTP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
3QK4U86953

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02569827 Phase 1/2 Dengue Fever Withdrawn SXTP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dengue Fever

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.